ผลของการใช้ยา Dolutegravir ร่วมกับยาต้านไวรัสอื่น ต่อระดับ Serum Creatinine eGFR และความชุกของความผิดปกติของไตในผู้ป่วยติดเชื้อเอชไอวี โรงพยาบาลโพนทอง : การศึกษาย้อนหลัง

Abstract

Retrospective Cohort Study in HIV-infected people receiving Antiretroviral drugs. Using data from the electronic medical record database, HOSxP Phon Thong Hospital, Roi Et Province, from 2000 – 31 Oct. 2023.Processed to analyze and compare Serum Creatinine (SCr) levels and estimated Glomerular Filtration Rate (eGFR) levels of Infected people receiving Antiretroviral drugs, before receiving the drugs, after receiving the drugs in weeks 4 and 52. Using One-way Repeated Measures ANOVA statistics, the results of the study. Found that in the group treated Dolutegravir combination with other Antiretroviral drugs, 85 people, when compared with the baseline values ​​of SCr levels, it was found that there was a  difference. There was a statistically significant difference (p<0.05) at weeks 4 (0.16 ± 0.02) and 52 (0.23 ± 0.18). The eGFR level was found to be a statistically significant difference (p<0.05) in weeks 4 (-12.83± 1.70) and 52 (-21.01 ± 1.15). While there were no changes in SCr and eGFR levels in people who receiving TDF+3TC+ EFV and TDF+FTC+EFV regimen. The prevalence of eGFR levels in the group treated with DTG Combination with  other Antiretroviral drugs was lead to chronic kidney disease It was found that in week 4 there were 7 people at level 3a. In week 52 there were 18 people. For level 3b in week 4 it was not found, but in week 52 there were 2 people. Conclusion  Dolutegravir used in combination with other Antiretroviral drugs resulted in a significant decrease in eGFR levels. Therefore, kidney function should be continuously monitored. Especially those whose eGFR level is lower than 80 ml/min /1.73 m2 to prevent adverse events from the drugs.